azelaic acid has been researched along with Acne Rosacea in 93 studies
nonanedioic acid : An alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topical azelaic acid (AzA) is a common treatment for mild/moderate inflammatory rosacea." | 9.41 | A novel azelaic acid formulation for the topical treatment of inflammatory rosacea: A multicentre, prospective clinical trial. ( Chiodini, P; Dall'Oglio, F; Fabbrocini, G; Lacarrubba, F; Micali, G; Skroza, N; Tedeschi, A, 2021) |
| "Topical azelaic acid (AA) is indicated for acne and rosacea, but there is some evidence for its use for other dermatological conditions." | 9.41 | A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. ( Campbell, J; Daly, ML; King, S; Maybury, C; Moncrieff, G; Rowe, R, 2023) |
| " A randomized, double-blind, vehicle-controlled, parallel-group, multicenter, phase 3 study was conducted in 961 participants to assess patient perception of efficacy, utility, and effect on quality of life (QOL) of an azelaic acid (AzA) 15% foam formulation for the treatment of papulopustular rosacea (PPR)." | 9.22 | Patient-reported outcomes of azelaic acid foam 15% for patients with papulopustular rosacea: secondary efficacy results from a randomized, controlled, double-blind, phase 3 trial. ( Lott, JP; Nkulikiyinka, R; Shakery, K; Solomon, JA; Staedtler, G; Tyring, S, 2016) |
| "Twice-daily azelaic acid (AzA) is the conventional regimen for papulopustular rosacea, but once-daily AzA may be equally effective, with greater convenience and dosing flexibility." | 9.13 | Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. ( Del Rosso, JQ; Fleischer, AB; Graupe, K; Thiboutot, DM, 2008) |
| "The objective of these studies was to evaluate the efficacy, tolerability, and safety of a new formulation of 15% azelaic acid (15%) gel (AzA gel), for the topical treatment of moderate, papulopustular rosacea." | 9.10 | Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. ( Graupe, K; Thiboutot, D; Thieroff-Ekerdt, R, 2003) |
| "75% metronidazole gel (MetroGel; Galderma Laboratories LP, Fort Worth, Tex) as topical therapy for moderate, papulopustular facial rosacea." | 9.10 | A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. ( Elewski, BE; Fleischer, AB; Pariser, DM, 2003) |
| "Previous investigations have indicated that topical azelaic acid has beneficial effects in rosacea." | 9.09 | Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. ( Bjerke, R; Fyrand, O; Graupe, K, 1999) |
| "In December of 2002, the FDA approved azelaic acid 15% gel for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea." | 8.84 | Azelaic acid (15% gel) in the treatment of acne rosacea. ( Gover, MD; Gupta, AK, 2007) |
| "To review published studies about topical metronidazole therapy for rosacea, both as a monotherapy and in conjunction with oral antibiotics." | 8.84 | Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. ( Balkrishnan, R; Conde, JF; Feldman, SR; Fleischer, AB; Yelverton, CB, 2007) |
| "To evaluate the clinical efficacy of topical 20% azelaic acid cream and 15% azelaic acid gel compared with their respective vehicles and metronidazole gel in the treatment of papulopustular rosacea." | 8.83 | Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. ( Basta, SA; Farmer, ER; Liu, RH; Smith, MK, 2006) |
| "Topical azelaic acid (AzA) is approved for the treatment of acne vulgaris and inflammatory (papulopustular) rosacea." | 8.83 | The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. ( Del Rosso, JQ, 2006) |
| "Azelaic acid is a naturally occurring, straight-chain dicarboxylic acid which is effective in the treatment of rosacea, presumably on account of its anti-inflammatory properties." | 8.82 | Azelaic acid 15% gel: in the treatment of papulopustular rosacea. ( Frampton, JE; Wagstaff, AJ, 2004) |
| "Objective: To describe patient characteristics, concerns, side effects, treatment satisfaction, and quality of life (QoL) of rosacea patients currently being treated with monotherapy azelaic acid foam based on patient-reported data." | 7.91 | Concerns and Treatment Satisfaction in Patients Being Treated With Azelaic Acid Foam for Rosacea ( Cameron, J; Gaiser, A; LaRose, A; Lott, J; McLeod, K; Quillen, A; Turner, B; Williamson, T, 2019) |
| "Rosacea is one of the most commonly occurring dermatoses treated by dermatologists." | 7.87 | Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. ( Jackson, JM; Kircik, LH; Lorenz, DJ, 2013) |
| "Azelaic acid (AzA) 15% gel has been available in the United States for slightly over a decade, approved for treatment of the inflammatory lesions (papules and pustules) of rosacea." | 7.80 | Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. ( Del Rosso, JQ; Kircik, LH, 2014) |
| "Azelaic acid (AzA) gel 15% is approved by the US Food and Drug Administration (FDA) for the treatment of papulopustular rosacea (PPR)." | 7.77 | Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application. ( Bhatia, N; Del Rosso, JQ, 2011) |
| "Azelaic acid has been found to inhibit the pathologic expression of cathelicidin, as well as the hyperactive protease activity that cleaves cathelicidin into LL-37." | 6.84 | Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of Rosacea. ( Henderson Berg, MH; Sadick, N; Wirth, PJ, 2017) |
| "Azelaic acid (AzA) is approved for the treatment of rosacea in a 15% gel formulation." | 6.80 | A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. ( Draelos, ZD; Elewski, BE; Harper, JC; Nkulikiyinka, R; Sand, M; Shakery, K; Staedtler, G, 2015) |
| " Two phase 3 trials have demonstrated that IVM 1% cream was significantly better than vehicle at investigator global assessment (IGA) success rate and lesion reductions and that it was safe and well tolerated." | 6.79 | Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. ( Appell, M; Draelos, Z; Fleischer, A; Fowler, J; Jackson, JM; Jacovella, J; Kircik, L; Liu, H; Lynde, C; Stein Gold, L; Steinhoff, M; Sugarman, J; Tan, J, 2014) |
| "Rosacea is a common chronic inflammatory skin disease that primarily affects facial skin." | 6.78 | Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. ( Draelos, ZD; Elewski, B; Havlickova, B; Staedtler, G, 2013) |
| "Rosacea is a leading reason why people seek the care of a dermatologist, accounting for nearly 7 million office visits annually." | 6.75 | Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. ( Bruce, S; Del Rosso, JQ; Jarratt, M; Menter, A; Staedtler, G, 2010) |
| "Rosacea is an inflammatory dermatologic disorder characterized by the presence of facial erythema, visible blood vessels, papules, and pustules." | 6.72 | Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. ( Arsonnaud, S; Kerrouche, N; Wolf, JE, 2006) |
| "Azelaic acid per se has multiple modes of action in rosacea, but an anti-inflammatory effect achieved by reducing reactive oxygen species appears to be the main pharmacological action." | 6.44 | Azelaic acid 15% gel in the treatment of rosacea. ( Gollnick, H; Layton, A, 2008) |
| "Metronidazole was the first topical therapy approved for rosacea and is still considered the foundation therapy by many researchers and dermatologists." | 6.42 | The role of topical metronidazole in the treatment of rosacea. ( Wolf, JE, 2004) |
| "Topical azelaic acid (AA) is indicated for acne and rosacea, but there is some evidence for its use for other dermatological conditions." | 5.41 | A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. ( Campbell, J; Daly, ML; King, S; Maybury, C; Moncrieff, G; Rowe, R, 2023) |
| "Topical azelaic acid (AzA) is a common treatment for mild/moderate inflammatory rosacea." | 5.41 | A novel azelaic acid formulation for the topical treatment of inflammatory rosacea: A multicentre, prospective clinical trial. ( Chiodini, P; Dall'Oglio, F; Fabbrocini, G; Lacarrubba, F; Micali, G; Skroza, N; Tedeschi, A, 2021) |
| " A randomized, double-blind, vehicle-controlled, parallel-group, multicenter, phase 3 study was conducted in 961 participants to assess patient perception of efficacy, utility, and effect on quality of life (QOL) of an azelaic acid (AzA) 15% foam formulation for the treatment of papulopustular rosacea (PPR)." | 5.22 | Patient-reported outcomes of azelaic acid foam 15% for patients with papulopustular rosacea: secondary efficacy results from a randomized, controlled, double-blind, phase 3 trial. ( Lott, JP; Nkulikiyinka, R; Shakery, K; Solomon, JA; Staedtler, G; Tyring, S, 2016) |
| "This two-phase, multicenter study was undertaken to examine the safety and efficacy of combination therapy with oral doxycycline and topical azelaic acid (AzA) 15% gel in moderate-to-severe papulopustular rosacea and to determine the effect of subsequent maintenance monotherapy with AzA 15% gel alone." | 5.14 | A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. ( Del Rosso, JQ; Fleischer, AB; Rich, P; Thiboutot, DM, 2009) |
| "Twice-daily azelaic acid (AzA) is the conventional regimen for papulopustular rosacea, but once-daily AzA may be equally effective, with greater convenience and dosing flexibility." | 5.13 | Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. ( Del Rosso, JQ; Fleischer, AB; Graupe, K; Thiboutot, DM, 2008) |
| "Topical ivermectin was more effective than metronidazole, but has a more concerning pregnancy category." | 5.12 | Treatment of rosacea during pregnancy. ( Cline, A; Gomolin, T; Pereira, F, 2021) |
| "75% metronidazole gel (MetroGel; Galderma Laboratories LP, Fort Worth, Tex) as topical therapy for moderate, papulopustular facial rosacea." | 5.10 | A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. ( Elewski, BE; Fleischer, AB; Pariser, DM, 2003) |
| "The objective of these studies was to evaluate the efficacy, tolerability, and safety of a new formulation of 15% azelaic acid (15%) gel (AzA gel), for the topical treatment of moderate, papulopustular rosacea." | 5.10 | Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. ( Graupe, K; Thiboutot, D; Thieroff-Ekerdt, R, 2003) |
| "Previous investigations have indicated that topical azelaic acid has beneficial effects in rosacea." | 5.09 | Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. ( Bjerke, R; Fyrand, O; Graupe, K, 1999) |
| "There was high quality evidence to support the effectiveness of topical azelaic acid, topical ivermectin, brimonidine, doxycycline and isotretinoin for rosacea." | 4.91 | Interventions for rosacea. ( Carter, B; Charland, L; Fedorowicz, Z; van der Linden, MM; van Zuuren, EJ, 2015) |
| "Although the majority of included studies were assessed as being at high or unclear risk of bias there was some evidence to support the effectiveness of topical metronidazole, azelaic acid, and doxycycline (40 mg) in the treatment of moderate to severe rosacea, and cyclosporine 0." | 4.87 | Interventions for rosacea. ( Carter, B; Fedorowicz, Z; Graber, MA; Kramer, S; van Zuuren, EJ, 2011) |
| "To review published studies about topical metronidazole therapy for rosacea, both as a monotherapy and in conjunction with oral antibiotics." | 4.84 | Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. ( Balkrishnan, R; Conde, JF; Feldman, SR; Fleischer, AB; Yelverton, CB, 2007) |
| "Topical azelaic acid (AzA) is approved for the treatment of acne vulgaris and inflammatory (papulopustular) rosacea." | 4.83 | The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. ( Del Rosso, JQ, 2006) |
| "To evaluate the clinical efficacy of topical 20% azelaic acid cream and 15% azelaic acid gel compared with their respective vehicles and metronidazole gel in the treatment of papulopustular rosacea." | 4.83 | Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. ( Basta, SA; Farmer, ER; Liu, RH; Smith, MK, 2006) |
| "Azelaic acid (AzA) initially was released in a 20% cream formulation, which has been shown to be effective in the treatment of mild to moderate rosacea." | 4.83 | A clinical overview of azelaic acid. ( Elewski, B; Thiboutot, D, 2006) |
| "Azelaic acid is a naturally occurring, straight-chain dicarboxylic acid which is effective in the treatment of rosacea, presumably on account of its anti-inflammatory properties." | 4.82 | Azelaic acid 15% gel: in the treatment of papulopustular rosacea. ( Frampton, JE; Wagstaff, AJ, 2004) |
| "Azelaic acid cream (20 percent) is a new topical treatment for acne with an additional therapeutic potential in rosacea and hyperpigmentation disorders." | 4.79 | Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. ( Cunliffe, WJ; Gollnick, HP; Graupe, K; Zaumseil, RP, 1996) |
| "Objective: To describe patient characteristics, concerns, side effects, treatment satisfaction, and quality of life (QoL) of rosacea patients currently being treated with monotherapy azelaic acid foam based on patient-reported data." | 3.91 | Concerns and Treatment Satisfaction in Patients Being Treated With Azelaic Acid Foam for Rosacea ( Cameron, J; Gaiser, A; LaRose, A; Lott, J; McLeod, K; Quillen, A; Turner, B; Williamson, T, 2019) |
| "Azelaic acid (AzA) 15% gel has been available in the United States for slightly over a decade, approved for treatment of the inflammatory lesions (papules and pustules) of rosacea." | 3.80 | Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. ( Del Rosso, JQ; Kircik, LH, 2014) |
| "Metronidazole and azelaic acid are the only topical medications approved for rosacea." | 3.79 | [Topical therapy of rosacea]. ( Schöfer, H, 2013) |
| " Cathelicidin/kallikrein-5 also provide a rationale for the effect of tetracyclines and azelaic acid against rosacea." | 3.77 | Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. ( Draelos, Z; Dréno, B; Elewski, BE; Jansen, T; Layton, A; Picardo, M, 2011) |
| "Azelaic acid (AzA) gel 15% is approved by the US Food and Drug Administration (FDA) for the treatment of papulopustular rosacea (PPR)." | 3.77 | Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application. ( Bhatia, N; Del Rosso, JQ, 2011) |
| "A range of treatment options are available in rosacea, which include several topical (mainly metronidazole, azelaic acid, other antibiotics, sulfur, retinoids) and oral drugs (mainly tetracyclines, metronidazole, macrolides)." | 3.77 | [Treatment of rosacea]. ( Cozzani, E; Drago, F; Gallo, R; Paolino, S; Parodi, A, 2011) |
| "Azelaic acid (AzA), a nine-carbon dicarboxylic acid, is an agent for the topical treatment of acne." | 3.76 | Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation. ( Aspite, N; Camera, E; Cardinali, G; Graupe, K; Izzo, E; Mastrofrancesco, A; Ottaviani, M; Picardo, M; Zouboulis, CC, 2010) |
| "Azelaic acid has been found to inhibit the pathologic expression of cathelicidin, as well as the hyperactive protease activity that cleaves cathelicidin into LL-37." | 2.84 | Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of Rosacea. ( Henderson Berg, MH; Sadick, N; Wirth, PJ, 2017) |
| "Acne and rosacea are common inflammatory skin conditions present in numerous racial and ethnic groups." | 2.82 | Acne and rosacea in skin of colour. ( Maruthappu, T; Taylor, M, 2022) |
| "Azelaic acid has numerous pharmacological uses in dermatology." | 2.82 | The versatility of azelaic acid in dermatology. ( Al-Niaimi, F; Ali, FR; Searle, T, 2022) |
| "Azelaic acid (AzA) is approved for the treatment of rosacea in a 15% gel formulation." | 2.80 | A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. ( Draelos, ZD; Elewski, BE; Harper, JC; Nkulikiyinka, R; Sand, M; Shakery, K; Staedtler, G, 2015) |
| " Two phase 3 trials have demonstrated that IVM 1% cream was significantly better than vehicle at investigator global assessment (IGA) success rate and lesion reductions and that it was safe and well tolerated." | 2.79 | Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. ( Appell, M; Draelos, Z; Fleischer, A; Fowler, J; Jackson, JM; Jacovella, J; Kircik, L; Liu, H; Lynde, C; Stein Gold, L; Steinhoff, M; Sugarman, J; Tan, J, 2014) |
| "Rosacea is a common chronic inflammatory skin disease that primarily affects facial skin." | 2.78 | Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. ( Draelos, ZD; Elewski, B; Havlickova, B; Staedtler, G, 2013) |
| "Rosacea is a prevalent inflammatory skin disorder that affects approximately 16 million individuals in the United States." | 2.75 | Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. ( Del Rosso, JQ, 2010) |
| "Rosacea is a leading reason why people seek the care of a dermatologist, accounting for nearly 7 million office visits annually." | 2.75 | Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. ( Bruce, S; Del Rosso, JQ; Jarratt, M; Menter, A; Staedtler, G, 2010) |
| "Azelaic acid cream was significantly more effective on inflammatory lesions but not erythema than the other two creams." | 2.74 | Comparative study of some treatment modalities of rosacea. ( Abdel Gawad, EH; Al Mokadem, S; El Harras, MA; Gomaa, SM; Mostafa, FF; Nassar, AA, 2009) |
| "Rosacea is an inflammatory dermatologic disorder characterized by the presence of facial erythema, visible blood vessels, papules, and pustules." | 2.72 | Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. ( Arsonnaud, S; Kerrouche, N; Wolf, JE, 2006) |
| "Papulopustular rosacea is characterized by papules and pustules in the central facial region." | 2.58 | A Review of the Current Modalities for the Treatment of Papulopustular Rosacea. ( Alinia, H; Feldman, SR; Fleischer, A; McGregor, SP; Snyder, A; Tuchayi, SM, 2018) |
| "Rosacea is an inflammatory condition of the skin, primarily affecting the central convexities of the face." | 2.53 | Topical and oral therapeutic approach to rosacea. ( Helfrich, YR; Maier, LM, 2016) |
| "Rosacea is a chronic facial inflammatory dermatosis characterized by background facial erythema and flushing and may be accompanied by inflammatory papules and pustules, cutaneous fibrosis and hyperplasia known as phyma, and ocular involvement." | 2.53 | Canadian Clinical Practice Guidelines for Rosacea. ( Asai, Y; Baibergenova, A; Barankin, B; Cochrane, CL; Humphrey, S; Lynde, CW; Marcoux, D; Poulin, Y; Rivers, JK; Sapijaszko, M; Sibbald, RG; Tan, J; Toole, J; Ulmer, M; Zip, C, 2016) |
| "Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans." | 2.52 | New and Emerging Treatments for Rosacea. ( Draelos, ZD; Gold, LM, 2015) |
| "Azelaic acid is a complex molecule with many diverse activities." | 2.52 | Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application. ( Rosen, T; Schulte, BC; Wu, W, 2015) |
| "Therefore, treating rosacea can greatly affect a person's quality of life." | 2.52 | Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. ( Gallo, RL; Hata, TR; Two, AM; Wu, W, 2015) |
| "The pathophysiology of papulopustular rosacea (PPR) is primarily characterized by inflammation associated with several factors such as abnormal innate immune response, neurovascular dysregulation, stratum corneum barrier dysfunction, and depletion of antioxidant reserve, with no definitive evidence supporting an underlying microbial etiology." | 2.48 | Optimal management of papulopustular rosacea: rationale for combination therapy. ( Bhatia, ND; Del Rosso, JQ, 2012) |
| "Rosacea is one of the most common chronic dermatological diseases." | 2.46 | [Rosacea: pathogenesis, clinical forms and therapy]. ( Kárpáti, S; Preisz, K, 2010) |
| "Rosacea is a common chronic inflammatory disease of the skin and is associated with a number of etiological causes and inciting factors." | 2.46 | A review of the diagnosis and treatment of rosacea. ( Berk, T; Scheinfeld, N, 2010) |
| "There are many options for the treatment of acne rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures." | 2.45 | Updates on the pathophysiology and management of acne rosacea. ( Choudhary, S; Elsaie, ML, 2009) |
| " Further interesting therapy options for the short- and long-term therapy of rosacea could be low-dose minocycline and isotretinoin; however, too little data are available with regard to the effectiveness, safety, optimal dosage and appropriate length of treatment for these medications to draw final conclusions." | 2.45 | Current topical and systemic approaches to treatment of rosacea. ( Korting, HC; Schöllmann, C, 2009) |
| "Azelaic acid per se has multiple modes of action in rosacea, but an anti-inflammatory effect achieved by reducing reactive oxygen species appears to be the main pharmacological action." | 2.44 | Azelaic acid 15% gel in the treatment of rosacea. ( Gollnick, H; Layton, A, 2008) |
| "Rosacea is a common chronic skin and ocular condition." | 2.44 | Systematic review of rosacea treatments. ( Gover, MD; Graber, M; Gupta, AK; Hollis, S; van Zuuren, EJ, 2007) |
| "The 3 primary agents for the topical treatment of rosacea are metronidazole, azelaic acid, and sodium sulfacetamide-sulfur." | 2.43 | Topical therapies for rosacea. ( Berson, DS; Nally, JB, 2006) |
| "Azelaic acid (AzA) is a naturally occurring dicarboxylic acid that has a long and complex history in the treatment of skin disorders." | 2.43 | The evolution of azelaic acid. ( Fleischer, AB, 2006) |
| "Because rosacea is a chronic condition, pharmacologic maintenance therapy is necessary to maintain remission." | 2.43 | Present and future rosacea therapy. ( Wolf, JE, 2005) |
| "Rosacea is a very common facial dermatosis." | 2.42 | Medical treatment of rosacea with emphasis on topical therapies. ( Del Rosso, JQ, 2004) |
| "Metronidazole was the first topical therapy approved for rosacea and is still considered the foundation therapy by many researchers and dermatologists." | 2.42 | The role of topical metronidazole in the treatment of rosacea. ( Wolf, JE, 2004) |
| "Rosacea is a chronic skin disorder associated with flushing, erythema, dryness, burning and stinging, and inflammatory papules and pustules." | 1.43 | Facial Dermatitis and Rosacea. ( Fowler, JF, 2016) |
| "Rosacea is a chronic facial skin disease that mainly occurs in people aged over 30 years." | 1.42 | Ivermectin cream for rosacea. ( , 2015) |
| "Acne vulgaris is a pervasive inflammatory disorder of the skin, with multiple etiologies and treatment options." | 1.40 | Acne vulgaris in the context of complex medical co-morbities: the management of severe acne vulgaris in a female with retinitis pigmentosa - utilizing pulse dye laser in conjunction with medical therapy. ( Keck, L; Shariff, A; Zlotoff, B, 2014) |
| "Rosacea is a common chronic skin disorder that has significant impact on the self-esteem and quality of life of affected individuals." | 1.38 | Rosacea: update on management and emerging therapies. ( Fallen, RS; Gooderham, M, 2012) |
| "Many options exist for the treatment of rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures." | 1.35 | Rosacea and its topical management. ( Gooderham, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.23) | 18.2507 |
| 2000's | 43 (46.24) | 29.6817 |
| 2010's | 41 (44.09) | 24.3611 |
| 2020's | 6 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Maruthappu, T | 1 |
| Taylor, M | 1 |
| King, S | 1 |
| Campbell, J | 1 |
| Rowe, R | 1 |
| Daly, ML | 1 |
| Moncrieff, G | 1 |
| Maybury, C | 1 |
| Fritsch, P | 1 |
| Kolber, MR | 1 |
| Korownyk, C | 1 |
| Searle, T | 1 |
| Ali, FR | 1 |
| Al-Niaimi, F | 1 |
| Buonomo, M | 1 |
| Ruggiero, JL | 1 |
| Warshaw, E | 1 |
| Dall'Oglio, F | 1 |
| Tedeschi, A | 1 |
| Lacarrubba, F | 1 |
| Fabbrocini, G | 1 |
| Skroza, N | 1 |
| Chiodini, P | 1 |
| Micali, G | 1 |
| Gomolin, T | 1 |
| Cline, A | 1 |
| Pereira, F | 1 |
| Wirth, PJ | 1 |
| Henderson Berg, MH | 1 |
| Sadick, N | 1 |
| McGregor, SP | 1 |
| Alinia, H | 1 |
| Snyder, A | 1 |
| Tuchayi, SM | 1 |
| Fleischer, A | 3 |
| Feldman, SR | 2 |
| McGee, JS | 1 |
| Wilkin, JK | 1 |
| Lev-Tov, H | 1 |
| Rill, JS | 1 |
| Liu, G | 1 |
| Kirby, JS | 1 |
| Williamson, T | 1 |
| Cameron, J | 1 |
| McLeod, K | 1 |
| Turner, B | 1 |
| Quillen, A | 1 |
| LaRose, A | 1 |
| Lott, J | 1 |
| Gaiser, A | 1 |
| Jackson, JM | 2 |
| Kircik, LH | 2 |
| Lorenz, DJ | 1 |
| Schöfer, H | 1 |
| Del Rosso, JQ | 16 |
| Gallo, RL | 3 |
| Tanghetti, E | 2 |
| Webster, G | 2 |
| Thiboutot, D | 5 |
| Coda, AB | 1 |
| Hata, T | 1 |
| Miller, J | 1 |
| Audish, D | 1 |
| Kotol, P | 1 |
| Two, A | 1 |
| Shafiq, F | 1 |
| Yamasaki, K | 1 |
| Harper, JC | 2 |
| Draelos, ZD | 6 |
| Elewski, B | 2 |
| Staedtler, G | 5 |
| Havlickova, B | 1 |
| Shariff, A | 1 |
| Keck, L | 1 |
| Zlotoff, B | 1 |
| Gallo, R | 2 |
| Eichenfield, LF | 1 |
| Stein-Gold, L | 1 |
| Berson, D | 1 |
| Zaenglein, A | 1 |
| Stein Gold, L | 1 |
| Kircik, L | 1 |
| Fowler, J | 1 |
| Tan, J | 2 |
| Draelos, Z | 2 |
| Appell, M | 1 |
| Steinhoff, M | 1 |
| Lynde, C | 1 |
| Sugarman, J | 1 |
| Liu, H | 1 |
| Jacovella, J | 1 |
| Two, AM | 1 |
| Wu, W | 2 |
| Hata, TR | 1 |
| van Zuuren, EJ | 4 |
| Fedorowicz, Z | 2 |
| Carter, B | 2 |
| van der Linden, MM | 1 |
| Charland, L | 1 |
| Lee, GL | 1 |
| Zirwas, MJ | 1 |
| Elewski, BE | 6 |
| Sand, M | 2 |
| Nkulikiyinka, R | 3 |
| Shakery, K | 3 |
| Schulte, BC | 1 |
| Rosen, T | 1 |
| Gold, LM | 1 |
| Asai, Y | 1 |
| Baibergenova, A | 1 |
| Barankin, B | 1 |
| Cochrane, CL | 1 |
| Humphrey, S | 1 |
| Lynde, CW | 1 |
| Marcoux, D | 1 |
| Poulin, Y | 1 |
| Rivers, JK | 1 |
| Sapijaszko, M | 1 |
| Sibbald, RG | 1 |
| Toole, J | 1 |
| Ulmer, M | 1 |
| Zip, C | 1 |
| Helfrich, YR | 1 |
| Maier, LM | 1 |
| Fowler, JF | 1 |
| Solomon, JA | 2 |
| Tyring, S | 2 |
| Lott, JP | 1 |
| Thiboutot, DM | 2 |
| Fleischer, AB | 6 |
| Graupe, K | 5 |
| Mostafa, FF | 1 |
| El Harras, MA | 1 |
| Gomaa, SM | 1 |
| Al Mokadem, S | 1 |
| Nassar, AA | 1 |
| Abdel Gawad, EH | 1 |
| Gollnick, H | 1 |
| Layton, A | 2 |
| Gooderham, M | 2 |
| Lehman, PA | 1 |
| Raney, SG | 1 |
| Korting, HC | 1 |
| Schöllmann, C | 1 |
| Rich, P | 1 |
| Elsaie, ML | 1 |
| Choudhary, S | 1 |
| Scheinfeld, N | 1 |
| Berk, T | 1 |
| Mastrofrancesco, A | 1 |
| Ottaviani, M | 1 |
| Aspite, N | 1 |
| Cardinali, G | 1 |
| Izzo, E | 1 |
| Zouboulis, CC | 1 |
| Camera, E | 1 |
| Picardo, M | 2 |
| Dréno, B | 1 |
| Jansen, T | 1 |
| Bruce, S | 1 |
| Jarratt, M | 1 |
| Menter, A | 1 |
| Preisz, K | 1 |
| Kárpáti, S | 1 |
| May, D | 1 |
| Kelsberg, G | 1 |
| Safranek, S | 1 |
| Kramer, S | 1 |
| Graber, MA | 2 |
| Parodi, A | 1 |
| Drago, F | 1 |
| Paolino, S | 1 |
| Cozzani, E | 1 |
| Bhatia, N | 1 |
| Bhatia, ND | 1 |
| Fallen, RS | 1 |
| Chauhan, N | 1 |
| Ellis, DA | 1 |
| Thieroff-Ekerdt, R | 1 |
| Pariser, DM | 1 |
| Wolf, JE | 3 |
| Bershad, S | 1 |
| Frampton, JE | 1 |
| Wagstaff, AJ | 1 |
| Gupta, AK | 3 |
| Czernielewski, J | 1 |
| Liu, Y | 1 |
| Lindow, KB | 1 |
| Punsalan, T | 1 |
| Usatine, RP | 1 |
| Roebuck, HL | 1 |
| Nally, JB | 1 |
| Berson, DS | 1 |
| Bikowski, JB | 1 |
| Kerrouche, N | 1 |
| Arsonnaud, S | 1 |
| Liu, RH | 1 |
| Smith, MK | 1 |
| Basta, SA | 1 |
| Farmer, ER | 1 |
| Green, BA | 1 |
| Edison, BL | 1 |
| Gover, MD | 2 |
| Graber, M | 1 |
| Hollis, S | 1 |
| Baum, EW | 1 |
| Kakita, LS | 1 |
| Colón, LE | 1 |
| Johnson, LA | 1 |
| Gottschalk, RW | 1 |
| Conde, JF | 1 |
| Yelverton, CB | 1 |
| Balkrishnan, R | 1 |
| Pariser, D | 1 |
| Maher, HK | 1 |
| Cunliffe, WJ | 1 |
| Gollnick, HP | 1 |
| Zaumseil, RP | 1 |
| Maddin, S | 1 |
| Bjerke, R | 1 |
| Fyrand, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Study to Investigate Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily in Subjects With Papulopustular Rosacea[NCT01025635] | Phase 2 | 401 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Potassium Titanyl Phosphate Laser Versus Pulsed Dye Laser for Rosacea - a Prospective Case-Control Study[NCT05771298] | 30 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | |||
| A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea[NCT01555463] | Phase 3 | 961 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily i[NCT00855595] | Phase 4 | 207 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01025635)
Timeframe: Baseline and End of treatment (up to 12 weeks) (LOCF)
| Intervention | Inflammatory lesions (Mean) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | -13.4 |
| Vehicle Foam | -9.5 |
(NCT01025635)
Timeframe: At End of treatment (up to 12 weeks) (LOCF)
| Intervention | Percentage of Inflammatory lesions (Mean) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | -62.5 |
| Vehicle Foam | -47.8 |
The IGA is a static evaluation of the overall severity of papulopustular rosacea at a given time. It consists of 5 scores ranging from clear to severe papulopustular rosacea and allows rapid overall evaluation of disease severity: 1) Clear: virtually no rosacea, ie, no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; residual to mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules; moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. Subjects achieving a clear, minimal, or mild IGA at the end of treatment were considered as 'responder'. Subjects with an IGA of moderate or severe at the end of treatment were considered as 'non-responder'. Subjects who prematurely withdraw from study treatment because of lack of efficacy were coded as 'non-responders'. (NCT01025635)
Timeframe: At End of treatment (up to 12 weeks) (LOCF)
| Intervention | Percentage of participants (Number) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | 69.2 |
| Vehicle Foam | 57.6 |
The IGA is a static evaluation of the overall severity of papulopustular rosacea at a given time. It consists of 5 scores ranging from clear to severe papulopustular rosacea and allows rapid overall evaluation of disease severity: 1) Clear: virtually no rosacea, ie, no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; residual to mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules; moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. Therapeutic success is defined as an IGA score of clear or minimal. (NCT01025635)
Timeframe: At End of treatment (up to 12 weeks) (LOCF)
| Intervention | Percentage of participants (Number) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | 43.4 |
| Vehicle Foam | 32.5 |
"The EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) is a standardized instrument for use as a measure of health outcome. The EQ-VAS asks for a judgment of the overall health status assessed by the participant her/himself. The 20-cm visual analog scale (VAS) has endpoints labeled best imaginable health state and worst imaginable health state that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day; higher scores indicate a better health state. The median (range) of the change, defined as EQ-VAS at end of treatment minus EQ-VAS at baseline, is presented." (NCT01555463)
Timeframe: Baseline and end of treatment, up to 12 weeks
| Intervention | Scores on a scale (Median) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | 0 |
| Vehicle Foam | 0 |
"The EuroQol Group Questionnaire-5 Dimensions-5 Levels (EQ-5D-5L) is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is used to assess the level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension is evaluated using 5 levels: no problems (level 1), slight problems (level 2), moderate problems (level 3), severe problems (level 4), and extreme problems (level 5). A scoring formula developed by EuroQol Group calculates a single index value from the results from all 5 domains along a continuum of 0 (death) to 1 (full health). The median (range) change, defined as the index value at end of treatment minus the index value at baseline, is presented." (NCT01555463)
Timeframe: Baseline and end of treatment, up to 12 weeks
| Intervention | Scores on a scale (Median) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | 0.000 |
| Vehicle Foam | 0.000 |
"The Rosacea Quality of Life (RosaQoL) is a questionnaire to evaluate the effect of rosacea on a participant's quality of life. Each of the 21 items in this questionnaire asks about the frequency with which a particular aspect of living with rosacea affects the participant: possible responses for each item are never (score=1), rarely (score=2), sometimes (score=3), often (score=4), or all the time (score=5). The overall score is the sum of the results from all 21 questions, with possible scores ranging from 21 (best) to 105 (worst); the higher the score, the more quality of life is impaired. The mean (standard deviation) of the change, defined as end of treatment overall score minus baseline overall score, is presented." (NCT01555463)
Timeframe: Baseline and end of treatment, up to 12 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | -6.8 |
| Vehicle Foam | -6.4 |
The mean (standard deviation) change from baseline in the inflammatory lesion count at the end of treatment is provided. (NCT01555463)
Timeframe: Baseline and end of treatment (LOCF), up to 12 weeks
| Intervention | Inflammatory lesions (Mean) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | -13.2 |
| Vehicle Foam | -10.3 |
The mean (standard deviation) lesion count at the end of treatment is provided. (NCT01555463)
Timeframe: At end of treatment (LOCF), up to 12 weeks
| Intervention | Inflammatory lesions (Mean) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | 8.5 |
| Vehicle Foam | 10.8 |
The mean (standard deviation) percentage change in inflammatory lesion count from baseline to end of study is provided. (NCT01555463)
Timeframe: Baseline and end of treatment (LOCF), up to 12 weeks
| Intervention | Percent change of inflammatory lesions (Mean) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | -61.6 |
| Vehicle Foam | -50.8 |
Participants achieving a clear, minimal, or mild IGA at the end of treatment were considered as 'responder'. Participants with an IGA of moderate or severe at the end of treatment were considered as 'non-responder'. Participants who prematurely withdraw from study treatment because of lack of efficacy were coded as 'non-responders'. The percentage of responders is presented. (NCT01555463)
Timeframe: At end of treatment (LOCF), up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | 66.3 |
| Vehicle Foam | 54.4 |
Static evaluation of overall severity of papulopustular rosacea at a given time: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. Therapeutic success is defined as an IGA score of clear or minimal. (NCT01555463)
Timeframe: At end of treatment (LOCF), up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Azelaic Acid Foam, 15% (BAY39-6251) | 32.1 |
| Vehicle Foam | 23.4 |
Erythema was rated as: clear or almost clear; mild; moderate; or severe. For the assessment of the grouped change in erythema ratings, the baseline examination was used to group into 'improved', 'no change', or 'worsened'. A participant was considered to have an 'improved' erythema rating if the erythema rating was lower compared to the baseline rating, 'no change' if the rating was identical, and 'worsened' if the rating was higher. The percentage of participants in each of these categories is presented. (NCT01555463)
Timeframe: Baseline and end of treatment (LOCF), up to 12 weeks
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Improved | No change | Worse | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 61.5 | 36.9 | 1.7 |
| Vehicle Foam | 51.3 | 46.2 | 2.5 |
Telangiectasia was rated as: no; mild; moderate; or severe. At the end of study, a participant was considered to have an 'improved' telangiectasia rating if the telangiectasia rating was lower compared to the baseline rating, 'no change' if the rating was identical, and 'worsened' if the rating was higher. The percentage of participants in each category is presented. (NCT01555463)
Timeframe: Baseline and end of treatment (LOCF), up to 12 weeks
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Improved | No change | Worse | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 27.3 | 65.8 | 6.8 |
| Vehicle Foam | 22.6 | 69.7 | 7.7 |
"The Dermatology Life Quality Index (DLQI) is a questionnaire consisting of a set of 10 questions that evaluate the degree to which the participant's skin has affected certain behaviors and quality of life over the past week. Possible responses to each question are: very much (question 7: yes) (score=3), a lot (score=2), a little (score=1), or not at all/not relevant (score=0). The DLQI overall score is the sum of the results from all 10 questions, with possible scores ranging from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The number of participants with score changes (end of treatment - baseline) in DLQI overall score from baseline to end of treatment <=-5 and >-5 are presented." (NCT01555463)
Timeframe: Baseline and end of treatment, up to 12 weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Score change <=-5 | Score change >-5 | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 107 | 328 |
| Vehicle Foam | 82 | 349 |
At the end of treatment, participants provided their opinion on local tolerability of the investigational product as excellent, good, acceptable despite minor irritation, less acceptable due to continuous irritation, non-acceptable, or no opinion. The number of participants in each category of this assessment is presented. (NCT01555463)
Timeframe: At end of treatment, up to 12 weeks
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Excellent | Good | Acceptable despite minor irritation | Less acceptable due to continuous irritation | Not acceptable | No opinion | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 167 | 128 | 112 | 15 | 6 | 7 |
| Vehicle Foam | 165 | 173 | 49 | 27 | 7 | 11 |
At the end of treatment, participants assessed the change of papulopustular rosacea from baseline (how it looked, felt, appeared to others) as excellent improvement, good improvement, fair improvement, no improvement, or worse. The number of participants in each category of this assessment is presented. (NCT01555463)
Timeframe: At end of treatment, up to 12 weeks
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Excellent improvement | Good improvement | Fair improvement | No improvement | Worse | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 75 | 174 | 121 | 57 | 8 |
| Vehicle Foam | 42 | 151 | 128 | 84 | 27 |
At the end of treatment, participants provided their opinion on cosmetic acceptability of the investigational product as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented. (NCT01555463)
Timeframe: At end of treatment, up to 12 weeks
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very good | Good | Satisfactory | Poor | No opinion | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 176 | 112 | 95 | 36 | 16 |
| Vehicle Foam | 124 | 142 | 99 | 46 | 21 |
At the end of treatment, participants provided their opinion on the practicability of the use of the investigational product in facial areas next to the hairline as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented. (NCT01555463)
Timeframe: At end of treatment, up to 12 weeks
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very good | Good | Satisfactory | Poor | No opinion | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 186 | 143 | 67 | 14 | 25 |
| Vehicle Foam | 155 | 151 | 75 | 27 | 24 |
The percentage of participants in each rating category of erythema (clear or almost clear; mild; moderate; severe) at the end of treatment is provided. (NCT01555463)
Timeframe: At end of treatment (LOCF), up to 12 weeks
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Clear or almost clear | Mild | Moderate | Severe | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 9.3 | 51.8 | 34.2 | 4.8 |
| Vehicle Foam | 8.4 | 41.8 | 43.1 | 6.7 |
Facial skin color (as compared with skin outside the treatment area) was rated as: normal; barely visible skin lightening; mild skin lightening; moderate skin lightening; severe skin lightening. The percentage of participants in each category of facial skin color at the end of study is presented. (NCT01555463)
Timeframe: At end of treatment (LOCF), up to 12 weeks
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Normal skin color | Barely visible skin-lightening | Mild skin lightening | Moderate skin lightening | Severe skin lightening | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 80.1 | 8.7 | 8.3 | 2.7 | 0.2 |
| Vehicle Foam | 78.7 | 10.5 | 7.7 | 3.1 | 0 |
The IGA consists of 5 scores: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. The percentage of participants with each score at the end of treatment is provided. (NCT01555463)
Timeframe: At end of treatment (LOCF), up to 12 weeks
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Clear | Minimal | Mild | Moderate | Severe | |
| Azelaic Acid Foam, 15% (BAY39-6251) | 4.6 | 27.5 | 34.2 | 30.2 | 3.5 |
| Vehicle Foam | 4.4 | 19.0 | 31.0 | 38.7 | 6.9 |
NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) (NCT00855595)
Timeframe: Baseline and Week 2
| Intervention | Inflammatory lesions (Mean) |
|---|---|
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | -10.5 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | -9.4 |
(NCT00855595)
Timeframe: Week 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Excellent Improvement | Marked Improvement | Moderate Improvement | No change | Deterioration | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 46.6 | 35.9 | 12.6 | 4.9 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 42.3 | 34.0 | 17.5 | 6.2 | 0 |
NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) (NCT00855595)
Timeframe: Baseline and Week 4, 6, 8 and 12
| Intervention | Inflammatory lesions (Mean) | |||
|---|---|---|---|---|
| Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | -13.2 | -14.8 | -15.5 | -16.2 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | -12.4 | -14.1 | -15.6 | -16.2 |
(NCT00855595)
Timeframe: Week 2, 4, 6, 8 and 12
| Intervention | Inflammatory lesions (Mean) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 10.1 | 7.4 | 5.9 | 5.1 | 4.4 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 12.5 | 9.5 | 7.8 | 6.4 | 5.7 |
(NCT00855595)
Timeframe: Week 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Very Good | Good | Satisfactory | Poor | No Opinion | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 52.0 | 34.3 | 4.9 | 0 | 8.8 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 56.3 | 26.0 | 8.3 | 1.0 | 8.3 |
(NCT00855595)
Timeframe: Week 12
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Excellent | Good | Acceptable despite minor irritation | Less acceptable due to continuous irritation | No opinion | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 53.9 | 34.3 | 7.8 | 2.9 | 1.0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 72.9 | 15.6 | 11.5 | 0 | 0 |
(NCT00855595)
Timeframe: Week 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Excellent Improvement | Good Improvement | Fair Improvement | No Improvement | Worse | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 51.0 | 39.2 | 7.8 | 2.0 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 49.0 | 33.3 | 15.6 | 1.0 | 1.0 |
NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) (NCT00855595)
Timeframe: Baseline and Week 2, 4, 6, 8 and 12
| Intervention | Percent of inflammatory lesions (Mean) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | -50.7 | -64.9 | -72.4 | -76.4 | -80.2 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | -43.0 | -56.9 | -64.5 | -71.6 | -75.1 |
(NCT00855595)
Timeframe: Baseline and Weeks 2, 4, 6, 8 and 12
| Intervention | Percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2, ≥25% improvement | Week 2, ≥50% improvement | Week 2, ≥75% improvement | Week 4, ≥25% improvement | Week 4, ≥50% improvement | Week 4, ≥75% improvement | Week 6, ≥25% improvement | Week 6, ≥50% improvement | Week 6, ≥75% improvement | Week 8, ≥25% improvement | Week 8, ≥50% improvement | Week 8, ≥75% improvement | Week 12, ≥25% improvement | Week 12, ≥50% improvement | Week 12, ≥75% improvement | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 84.9 | 61.3 | 20.8 | 90.6 | 75.5 | 44.3 | 95.3 | 84.9 | 54.7 | 95.3 | 88.7 | 67.0 | 96.2 | 89.6 | 68.9 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 77.2 | 47.5 | 17.8 | 81.2 | 64.4 | 40.6 | 91.1 | 78.2 | 43.6 | 90.1 | 87.1 | 55.4 | 91.1 | 85.1 | 65.3 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information) / Patient response is defined as an IGA score of clear, minimal, or mild (0, 1, or 2) (NCT00855595)
Timeframe: Weeks 2, 4, 6, 8 and 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 32.1 | 55.7 | 60.4 | 72.6 | 78.3 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 27.7 | 44.6 | 53.5 | 59.4 | 72.3 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information) / Therapeutic success is defined as an IGA score of clear or minimal (0 or 1). (NCT00855595)
Timeframe: Weeks 2, 4, 6, 8 and 12
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 13.2 | 32.1 | 45.3 | 50.9 | 62.3 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 7.9 | 26.7 | 27.7 | 39.6 | 52.5 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 12
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 30.2 | 32.1 | 16.0 | 12.3 | 6.6 | 1.9 | 0.9 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 22.8 | 29.7 | 19.8 | 13.9 | 10.9 | 3.0 | 0 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 2
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 0.9 | 12.3 | 18.9 | 33.0 | 25.5 | 9.4 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 1.0 | 6.9 | 19.8 | 31.7 | 27.7 | 10.9 | 2.0 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 4
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 7.5 | 24.5 | 23.6 | 24.5 | 15.1 | 4.7 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 6.9 | 19.8 | 17.8 | 23.8 | 20.8 | 9.9 | 1.0 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 6
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 18.9 | 26.4 | 15.1 | 24.5 | 11.3 | 3.8 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 9.9 | 17.8 | 25.7 | 19.8 | 19.8 | 6.9 | 0 |
IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). (NCT00855595)
Timeframe: At Week 8
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 - Clear | 1 - Minimal | 2 - Mild | 3 - Mild to moderate | 4 - Moderate | 5 - Moderate to severe | 6 - Severe | |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) | 18.9 | 32.1 | 21.7 | 14.2 | 10.4 | 2.8 | 0 |
| Metronidazole (Metrogel) Plus Doxycycline (Oracea) | 13.9 | 25.7 | 19.8 | 23.8 | 12.9 | 4.0 | 0 |
41 reviews available for azelaic acid and Acne Rosacea
| Article | Year |
|---|---|
Acne and rosacea in skin of colour.
Topics: Acne Vulgaris; Adapalene; Diagnosis, Differential; Dicarboxylic Acids; Humans; Racial Groups; Rosace | 2022 |
A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging.
Topics: Acne Vulgaris; Dermatologic Agents; Erythema; Humans; Melanosis; Rosacea; Skin Aging; Treatment Outc | 2023 |
The versatility of azelaic acid in dermatology.
Topics: Acne Vulgaris; Dermatologic Agents; Dermatology; Dicarboxylic Acids; Humans; Male; Rosacea | 2022 |
Treatment of rosacea during pregnancy.
Topics: Adult; Algorithms; Animals; Anti-Bacterial Agents; Azithromycin; Brimonidine Tartrate; Dermatologic | 2021 |
A Review of the Current Modalities for the Treatment of Papulopustular Rosacea.
Topics: Administration, Cutaneous; Anti-Infective Agents; Dermatologic Agents; Dicarboxylic Acids; Doxycycli | 2018 |
Rosacea First-choice treatments.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Bacteria | 2017 |
Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea.
Topics: Administration, Cutaneous; Administration, Oral; Delayed-Action Preparations; Dermatologic Agents; D | 2013 |
An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea.
Topics: Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Humans; Immunity, Innate; Inflammation; Low-Le | 2013 |
Rosacea: part II. Topical and systemic therapies in the treatment of rosacea.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Calcineurin Inhibitors; Dicarboxylic Acids; Huma | 2015 |
Interventions for rosacea.
Topics: Anti-Infective Agents; Brimonidine Tartrate; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; | 2015 |
Granulomatous Rosacea and Periorificial Dermatitis: Controversies and Review of Management and Treatment.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Benzoyl Peroxide; Dermatitis, Perioral; Dermatologic | 2015 |
Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application.
Topics: Acne Vulgaris; Alopecia Areata; Dermatitis, Perioral; Dermatologic Agents; Dicarboxylic Acids; Facia | 2015 |
New and Emerging Treatments for Rosacea.
Topics: Administration, Topical; Brimonidine Tartrate; Clinical Trials, Phase III as Topic; Dermatologic Age | 2015 |
Canadian Clinical Practice Guidelines for Rosacea.
Topics: Anti-Infective Agents; Consensus; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Eye Diseases | 2016 |
Topical and oral therapeutic approach to rosacea.
Topics: Administration, Cutaneous; Administration, Oral; Brimonidine Tartrate; Dermatologic Agents; Dicarbox | 2016 |
Azelaic acid 15% gel in the treatment of rosacea.
Topics: Administration, Topical; Dermatologic Agents; Dicarboxylic Acids; Gels; Humans; Randomized Controlle | 2008 |
Current topical and systemic approaches to treatment of rosacea.
Topics: Administration, Oral; Administration, Topical; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; | 2009 |
Updates on the pathophysiology and management of acne rosacea.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Dermatologic Agents; Dicarboxy | 2009 |
A review of the diagnosis and treatment of rosacea.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Dermato | 2010 |
[Rosacea: pathogenesis, clinical forms and therapy].
Topics: Administration, Cutaneous; Administration, Oral; Anti-Infective Agents; Anti-Infective Agents, Local | 2010 |
Clinical inquiries. What is the most effective treatment for acne rosacea?
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Dermato | 2011 |
Interventions for rosacea.
Topics: Anti-Infective Agents; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Humans; M | 2011 |
Optimal management of papulopustular rosacea: rationale for combination therapy.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agents; Dermatologic Agents; Dica | 2012 |
Rosacea: pathophysiology and management principles.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Benzoyl Peroxide; Dermatologic | 2013 |
A status report on the medical management of rosacea: focus on topical therapies.
Topics: Administration, Topical; Anti-Infective Agents; Anti-Infective Agents, Local; Dermatologic Agents; D | 2002 |
Medical treatment of rosacea with emphasis on topical therapies.
Topics: Administration, Topical; Anti-Infective Agents, Local; Clinical Trials as Topic; Dermatologic Agents | 2004 |
The role of topical metronidazole in the treatment of rosacea.
Topics: Administration, Topical; Anti-Infective Agents; Dicarboxylic Acids; Humans; Metronidazole; Rosacea | 2004 |
Azelaic acid 15% gel: in the treatment of papulopustular rosacea.
Topics: Administration, Cutaneous; Dermatologic Agents; Dicarboxylic Acids; Gels; Humans; Randomized Control | 2004 |
Rosacea. An overview of diagnosis and management.
Topics: Anti-Infective Agents; Body Image; Dermatologic Agents; Diagnosis, Differential; Dicarboxylic Acids; | 2004 |
Present and future rosacea therapy.
Topics: Anti-Infective Agents; Biomedical Research; Chronic Disease; Dermatologic Agents; Dicarboxylic Acids | 2005 |
The rigor of trials evaluating Rosacea treatments.
Topics: Anti-Infective Agents; Dermatologic Agents; Dicarboxylic Acids; Gels; Humans; Metronidazole; Randomi | 2005 |
Face up to rosacea.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Dermatologic Agents; Diagnosis, Differential; Dicar | 2005 |
Topical therapies for rosacea.
Topics: Administration, Topical; Dicarboxylic Acids; Humans; Metronidazole; Rosacea; Sulfacetamide | 2006 |
The evolution of azelaic acid.
Topics: Acne Vulgaris; Dermatologic Agents; Dicarboxylic Acids; Humans; Hyperpigmentation; Rosacea; Skin Dis | 2006 |
A clinical overview of azelaic acid.
Topics: Administration, Cutaneous; Chemistry, Pharmaceutical; Dermatologic Agents; Dicarboxylic Acids; Human | 2006 |
The use of topical azelaic acid for common skin disorders other than inflammatory rosacea.
Topics: Administration, Cutaneous; Dermatitis, Perioral; Dermatologic Agents; Dicarboxylic Acids; Humans; Me | 2006 |
Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials.
Topics: Administration, Cutaneous; Dermatologic Agents; Dicarboxylic Acids; Humans; Randomized Controlled Tr | 2006 |
Systematic review of rosacea treatments.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Benzoyl Peroxide; Cosmetics; | 2007 |
Azelaic acid (15% gel) in the treatment of acne rosacea.
Topics: Dermatologic Agents; Dicarboxylic Acids; Gels; Humans; Ointments; Randomized Controlled Trials as To | 2007 |
Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Dermatologic Agents; Dicarboxylic Acids; Doxycyclin | 2007 |
Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports.
Topics: Acne Vulgaris; Administration, Topical; Clinical Trials as Topic; Dermatologic Agents; Dicarboxylic | 1996 |
22 trials available for azelaic acid and Acne Rosacea
| Article | Year |
|---|---|
A novel azelaic acid formulation for the topical treatment of inflammatory rosacea: A multicentre, prospective clinical trial.
Topics: Dermatologic Agents; Dicarboxylic Acids; Humans; Prospective Studies; Rosacea; Treatment Outcome | 2021 |
Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of Rosacea.
Topics: Administration, Cutaneous; Dermatologic Agents; Dicarboxylic Acids; Facial Dermatoses; Gels; Humans; | 2017 |
Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea.
Topics: Administration, Cutaneous; Administration, Oral; Delayed-Action Preparations; Dermatologic Agents; D | 2013 |
Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Dicarboxylic Acids; | 2013 |
Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Dicarbox | 2014 |
A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea.
Topics: Administration, Cutaneous; Adult; Aged; Chronic Disease; Dermatologic Agents; Dicarboxylic Acids; Do | 2015 |
Investigator-reported efficacy of azelaic acid foam 15% in patients with papulopustular rosacea: secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial.
Topics: Administration, Cutaneous; Dermatologic Agents; Dicarboxylic Acids; Dosage Forms; Double-Blind Metho | 2016 |
Patient-reported outcomes of azelaic acid foam 15% for patients with papulopustular rosacea: secondary efficacy results from a randomized, controlled, double-blind, phase 3 trial.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Dicarboxylic Acids; | 2016 |
Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea.
Topics: Dermatologic Agents; Dicarboxylic Acids; Drug Administration Schedule; Female; Gels; Humans; Male; M | 2008 |
Comparative study of some treatment modalities of rosacea.
Topics: Adult; Dicarboxylic Acids; Double-Blind Method; Female; Humans; Male; Metronidazole; Middle Aged; Pe | 2009 |
A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agen | 2009 |
The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the Assessment of Skin Characteristics Study.
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Dicarboxylic Acids; Drug Therapy, Combination | 2009 |
Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Dicarboxylic Acids; Doxycycline; Drug Th | 2010 |
Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Delayed | 2010 |
Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies.
Topics: Adult; Aged; Aged, 80 and over; Dermatologic Agents; Dicarboxylic Acids; Female; Gels; Humans; Male; | 2003 |
A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Dicarboxylic Acids; Do | 2003 |
Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel.
Topics: Administration, Cutaneous; Adult; Aged; Dermatologic Agents; Dicarboxylic Acids; Epidermis; Female; | 2004 |
Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea.
Topics: Administration, Cutaneous; Adult; Aged; Dermatologic Agents; Dicarboxylic Acids; Drug Administration | 2006 |
An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients.
Topics: Dermatologic Agents; Dicarboxylic Acids; Erythema; Female; Gels; Humans; Inflammation; Rosacea; Sing | 2006 |
Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%.
Topics: Administration, Topical; Adult; Dermatologic Agents; Dicarboxylic Acids; Drug Eruptions; Female; Gel | 2007 |
A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea.
Topics: Administration, Topical; Adult; Aged; Dermatologic Agents; Dicarboxylic Acids; Double-Blind Method; | 1999 |
Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea.
Topics: Administration, Cutaneous; Adolescent; Adult; Dermatologic Agents; Dicarboxylic Acids; Double-Blind | 1999 |
31 other studies available for azelaic acid and Acne Rosacea
| Article | Year |
|---|---|
Topical treatments for rosacea.
Topics: Administration, Topical; Dicarboxylic Acids; Drug Costs; Humans; Ivermectin; Metronidazole; Patient | 2019 |
Contact dermatitis from an azelaic acid-containing gel.
Topics: Administration, Cutaneous; Dermatitis, Allergic Contact; Dermatologic Agents; Dicarboxylic Acids; Hu | 2021 |
Prescription to Over-the-Counter Switch of Metronidazole and Azelaic Acid for Treatment of Rosacea.
Topics: Anti-Infective Agents; Dermatologic Agents; Diagnostic Self Evaluation; Dicarboxylic Acids; Humans; | 2018 |
Trends in utilization of topical medications for treatment of rosacea in the United States (2005-2014): A cohort analysis.
Topics: Administration, Cutaneous; Adult; Anti-Bacterial Agents; Cohort Studies; Dermatologic Agents; Dicarb | 2019 |
Concerns and Treatment Satisfaction in Patients Being Treated With Azelaic Acid Foam for Rosacea
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Dicarboxylic Acids; Female; Humans; Male; Mid | 2019 |
[Topical therapy of rosacea].
Topics: Administration, Topical; Anti-Inflammatory Agents; Dermatologic Agents; Dicarboxylic Acids; Humans; | 2013 |
Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.
Topics: Administration, Topical; Adult; Aged; Animals; Antimicrobial Cationic Peptides; Biomarkers; Cathelic | 2013 |
Acne vulgaris in the context of complex medical co-morbities: the management of severe acne vulgaris in a female with retinitis pigmentosa - utilizing pulse dye laser in conjunction with medical therapy.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Androstenes; Anti-Infective Agents, Local; Combined | 2014 |
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Infectiv | 2014 |
Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid.
Topics: Administration, Cutaneous; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Drug Therapy, Combi | 2014 |
Ivermectin cream for rosacea.
Topics: Adult; Clinical Trials as Topic; Dicarboxylic Acids; Drug Interactions; Humans; Ivermectin; Metronid | 2015 |
Facial Dermatitis and Rosacea.
Topics: Adrenal Cortex Hormones; Adrenergic alpha-2 Receptor Agonists; Antimicrobial Cationic Peptides; Anti | 2016 |
Rosacea and its topical management.
Topics: Administration, Cutaneous; Dermatologic Agents; Dicarboxylic Acids; Humans; Metronidazole; Rosacea; | 2009 |
Impact of order of application of moisturizers on percutaneous absorption kinetics: evaluation of sequential application of moisturizer lotions and azelaic acid gel 15% using a human skin model.
Topics: Administration, Topical; Dermatologic Agents; Dicarboxylic Acids; Drug Combinations; Emollients; Hum | 2009 |
Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation.
Topics: Acne Vulgaris; Cells, Cultured; Cytokines; Dermatologic Agents; Dicarboxylic Acids; Drug Evaluation, | 2010 |
Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group.
Topics: Algorithms; Cosmetics; Dicarboxylic Acids; Humans; International Cooperation; Patient Education as T | 2011 |
[Treatment of rosacea].
Topics: Adapalene; Anti-Infective Agents; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; Humans; Imm | 2011 |
Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Dermatologic Agents; Dicarbo | 2011 |
Rosacea: update on management and emerging therapies.
Topics: Administration, Cutaneous; Adrenergic Agents; Anti-Infective Agents; Antiparasitic Agents; Brimonidi | 2012 |
Azelaic acid (Finacea) for rosacea.
Topics: Administration, Topical; Dermatologic Agents; Dicarboxylic Acids; Dose-Response Relationship, Drug; | 2003 |
Azelaic acid: a viewpoint by Susan Bershad.
Topics: Dermatologic Agents; Dicarboxylic Acids; Humans; Rosacea | 2004 |
Azelaic acid : a viewpoint by Aditya K. Gupta.
Topics: Dermatologic Agents; Dicarboxylic Acids; Humans; Rosacea | 2004 |
New rosacea drug gets the red out.
Topics: Dermatologic Agents; Dicarboxylic Acids; Humans; Rosacea | 2004 |
Azelaic acid, a new treatment for rosacea.
Topics: Dermatologic Agents; Dicarboxylic Acids; Humans; Rosacea | 2004 |
Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dermatologic Agents; Dicarboxylic Acids; Gels; | 2004 |
Red facial rash with "granitos".
Topics: Anti-Bacterial Agents; Dermatologic Agents; Diagnosis, Differential; Dicarboxylic Acids; Disease Pro | 2005 |
Case studies.
Topics: Administration, Cutaneous; Adult; Dermatitis, Seborrheic; Dermatologic Agents; Diagnosis, Differenti | 2006 |
Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%.
Topics: Anti-Infective Agents; Dermatologic Agents; Dicarboxylic Acids; Drug Administration Schedule; Humans | 2007 |
Azelaic acid gel 15%: clinical versatility in the treatment of rosacea.
Topics: Dermatologic Agents; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Administration Sched | 2006 |
In reference to the October 2004 comprehensive overview of rosacea therapy.
Topics: Clinical Trials as Topic; Dermatologic Agents; Dicarboxylic Acids; Humans; Metronidazole; Rosacea | 2007 |
Rosacea.
Topics: Anti-Bacterial Agents; Chronic Disease; Dermatologic Agents; Dicarboxylic Acids; Humans; Risk Factor | 2007 |